human genome sciences
July 20th, 2009
Human Genome Sciences Inc. (NASDAQ: HGSI) is going to be the top price leader this morning. It and GlaxoSmithKline (GSK) have announced that the BENLYSTA study met the primary endpoint in BLISS-52, the first of two pivotal Phase III The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult Benlysta is first new medicine to succeed against disease in 50 years. Benlysta improved symptoms of lupus without any sign of worsening others in an.